Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CTLA-4: a moving target in immunotherapy.

Literature DB >> 29118008

CTLA-4: a moving target in immunotherapy.

Behzad Rowshanravan¹, Neil Halliday¹, David M Sansom¹.

Abstract

CD28 and CTLA-4 are members of a family of immunoglobulin-related receptors that are responsible for various aspects of T-cell immune regulation. The family includes CD28, CTLA-4, and ICOS as well as other proteins, including PD-1, BTLA, and TIGIT. These receptors have both stimulatory (CD28, ICOS) and inhibitory roles (CTLA-4, PD-1, BTLA, and TIGIT) in T-cell function. Increasingly, these pathways are targeted as part of immune modulatory strategies to treat cancers, referred to generically as immune checkpoint blockade, and conversely to treat autoimmunity and CTLA-4 deficiency. Here, we focus on the biology of the CD28/CTLA-4 pathway as a framework for understanding the impacts of therapeutic manipulation of this pathway.

Entities: Chemical

Mesh：

Substances：

Year: 2017 PMID： 29118008 PMCID： PMC6317697 DOI： 10.1182/blood-2017-06-741033

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

135 in total

1. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses.

Authors: C C Stamper; Y Zhang; J F Tobin; D V Erbe; S Ikemizu; S J Davis; M L Stahl; J Seehra; W S Somers; L Mosyak
Journal: Nature Date: 2001-03-29 Impact factor: 49.962

2. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex.

Authors: J C Schwartz; X Zhang; A A Fedorov; S G Nathenson; S C Almo
Journal: Nature Date: 2001-03-29 Impact factor: 49.962

3. A cellular calculus for signal integration by T cells.

Authors: A V Gett; P D Hodgkin
Journal: Nat Immunol Date: 2000-09 Impact factor: 25.606

4. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses.

Authors: R Khattri; J A Auger; M D Griffin; A H Sharpe; J A Bluestone
Journal: J Immunol Date: 1999-05-15 Impact factor: 5.422

5. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.

Authors: A van Elsas; A A Hurwitz; J P Allison
Journal: J Exp Med Date: 1999-08-02 Impact factor: 14.307

6. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes.

Authors: B Salomon; D J Lenschow; L Rhee; N Ashourian; B Singh; A Sharpe; J A Bluestone
Journal: Immunity Date: 2000-04 Impact factor: 31.745

7. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.

Authors: A A Hurwitz; B A Foster; E D Kwon; T Truong; E M Choi; N M Greenberg; M B Burg; J P Allison
Journal: Cancer Res Date: 2000-05-01 Impact factor: 12.701

8. Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous.

Authors: M F Bachmann; G Köhler; B Ecabert; T W Mak; M Kopf
Journal: J Immunol Date: 1999-08-01 Impact factor: 5.422

9. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.

Authors: R P Sutmuller; L M van Duivenvoorde; A van Elsas; T N Schumacher; M E Wildenberg; J P Allison; R E Toes; R Offringa; C J Melief
Journal: J Exp Med Date: 2001-09-17 Impact factor: 14.307

10. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy.

Authors: A van Elsas; R P Sutmuller; A A Hurwitz; J Ziskin; J Villasenor; J P Medema; W W Overwijk; N P Restifo; C J Melief; R Offringa; J P Allison
Journal: J Exp Med Date: 2001-08-20 Impact factor: 14.307

219 in total

Review 1. A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer.

Authors: Yunes Panahi; Amir Hossein Mohammadzadeh; Behzad Behnam; Hossein M Orafai; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal: Adv Exp Med Biol Date: 2021 Impact factor: 2.622

Review 2. IFN-γ: A cytokine at the right time, is in the right place.

Authors: J Daniel Burke; Howard A Young
Journal: Semin Immunol Date: 2019-06-17 Impact factor: 11.130

3. The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis.

Authors: Karthik Suresh; Jarushka Naidoo; Qiong Zhong; Ye Xiong; Jennifer Mammen; Marcia Villegas de Flores; Laura Cappelli; Aanika Balaji; Tsvi Palmer; Patrick M Forde; Valsamo Anagnostou; David S Ettinger; Kristen A Marrone; Ronan J Kelly; Christine L Hann; Benjamin Levy; Josephine L Feliciano; Cheng-Ting Lin; David Feller-Kopman; Andrew D Lerner; Hans Lee; Majid Shafiq; Lonny Yarmus; Evan J Lipson; Mark Soloski; Julie R Brahmer; Sonye K Danoff; Franco D'Alessio
Journal: J Clin Invest Date: 2019-07-16 Impact factor: 14.808

CTLA-4: a moving target in immunotherapy.

1. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses.

2. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex.

3. A cellular calculus for signal integration by T cells.

4. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses.

5. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.

6. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes.

7. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.

8. Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous.

9. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.

10. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy.

Review 1. A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer.

Review 2. IFN-γ: A cytokine at the right time, is in the right place.

3. The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis.

Review 4. Biomaterials for vaccine-based cancer immunotherapy.

Review 5. The role of proteomics in the age of immunotherapies.

6. Identification of susceptibility SNPs in CTLA-4 and PTPN22 for scleritis in Han Chinese.

Review 7. Nanomaterial-Based Modulation of Tumor Microenvironments for Enhancing Chemo/Immunotherapy.

Review 8. Phosphoinositide 3-kinase δ is a regulatory T-cell target in cancer immunotherapy.

Review 9. Advances in targeted therapy for malignant lymphoma.

10. Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression.